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SUMMARY Malignant glioblastomas are the most common and lethal adult brain tumours, with patients dying within two years from diagnosis. Little is known about
the molecular mechanisms underlying the formation and/or development of these tumours, which present a very invasive phenotype within the brain and are genetically
heterogeneous and highly resistant to both chemo- and radio-therapies. Recently, the promoter region of the protein kinase WNK2 gene was found to be hypermethylated
in 29 of 31 infiltrative gliomas and about 80% of meningiomas. We have previously described that the experimental depletion of WNK2 expression decreases RhoA
activity whilst leading to increased Rac1 activity. Because RhoA/Rac1 activities are important for cell migration and glioblastomas are very invasive tumours, we tested
the effects of WNK2 on wound-healing assays in glioma cell lines SW1088 and A172. SW1088 cells express endogenous WNK2 and we observed that wound closure
was increased upon experimental depletion of endogenous WNK2. In contrast, A172 cells display complete promoter region methylation and WNK2 re-expression was
found to decrease migration. Consistently, we observed an increase in Rac1 activity in SW1088 cells upon WNK2 down-regulation, but lower levels of active Rac1 in
A172 cells stably expressing WNK2 cDNA when compared with an equivalent cell line stably transfected with the same empty vector. Our studies indicate that loss of
WNK2 expression promotes Rac1 activation and may contribute to the highly invasive phenotype that glioblastomas present. We also observed that, in a panel of
glioblastoma cell lines, WNK2 promoter methylation correlates with a marked deregulation in Akt, MEK1/2 and ERK1/2 activities, suggesting WNK2 may also be
important for tumour cell survival and cell cycle progression.
WNK2 expression in glioblastoma cell lines
WNK2
transcript
Pol II
RT-PCR WB
WNK2
a-tubulin
Depletion of endogenous WNK2 in SW1088 cells leads to 
increased wound closure in scratch assays
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Stable WNK2 re-expression in A172 cells retards wound closure in scratch 
assays…
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A172 cell line (parental), with total WNK2 promotor
methylation, was stably transfected with pcDNA3-Hygro-
EV (A172HEv) or pcDNA3-Hygro-WNK2 (A172HW2).
WNK2 expression was confirmed by immunoprecipitation
with an anti-WNK2 specific antibody or a non-specific
serum
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Conclusions:
• WNK2 experimental depletion originates a phenotype of increased cell migration and Rac1 activity, supporting that it plays a role in
regulating the characteristic invasiveness of these tumours.
•WNK2 epigenetic silencing correlates with the increased activity of key regulators of cell proliferation and survival, suggesting an
important role for this protein kinase in glioblastoma development.
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Endogenous WNK2 depletion results in increased Rac1 
activity, while its re-expression reduces active Rac1
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WNK2 promotor methylation correlates with increased Akt, 
MEK1 and ERK1/2 activities
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